CyanoCapture and Persist AI to Build World’s First Robotic GMP Facility for Oral Protein and Peptide Drugs
CyanoCapture and Persist AI announced a collaboration to build a GMP manufacturing facility in the San Francisco Bay Area, operational by Q4 2026. This facility will integrate cyanobacteria-based drug delivery with AI-driven robotics for the production of oral protein and peptide therapeutics, addressing the challenge of delivering biologics orally instead of via injection. The partnership aims to enhance drug development speed and precision using AI in the manufacturing process.
Theia Market Signal Identification - AI Assisted
CyanoCapture and Persist AI are collaborating to construct the first GMP manufacturing facility combining cyanobacteria culture with AI-driven robotics, set to be operational by Q4 2026 in the San Francisco Bay Area. This facility will facilitate the clinical-scale production of novel oral protein and peptide drugs, addressing the challenge of delivering these biologics orally.
The project will utilize CyanoCapture's cyanobacterial platform and Persist AI's robotic systems for formulation development and production optimization. Initial efforts will focus on converting injectable biologics into oral formulations, utilizing machine learning for enhanced research and development.
Comments